MindBio Therapeutics Corp. (CSE:MBIO)
Canada · Delayed Price · Currency is CAD 0.2500
0.00 (0.00%)
At close: Aug 10, 2026
MindBio Therapeutics Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 0.07 | 0.06 | 0.14 | 0.32 | 1.31 |
Short-Term Investments | - | - | - | 0.01 | 0.03 |
Cash & Short-Term Investments | 0.07 | 0.06 | 0.14 | 0.33 | 1.35 |
Cash Growth | 374.40% | -53.83% | -58.48% | -75.22% | - |
Other Receivables | 1.12 | 0.05 | 0.06 | 0.05 | 0.05 |
Receivables | 1.12 | 0.05 | 0.06 | 0.05 | 0.05 |
Restricted Cash | - | - | - | 0.28 | 0.22 |
Total Current Assets | 1.19 | 0.12 | 0.19 | 0.67 | 1.61 |
Total Assets | 1.19 | 0.12 | 0.19 | 0.67 | 1.61 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 0.17 | 0.17 | 0.23 | 0.57 | 0.05 |
Accrued Expenses | 0.11 | 0.15 | 0.08 | 0.08 | 1.15 |
Current Portion of Long-Term Debt | 2.24 | 2.24 | 4.98 | 2.16 | - |
Current Unearned Revenue | - | - | - | 0.12 | - |
Total Current Liabilities | 2.52 | 2.56 | 5.29 | 2.93 | 1.19 |
Long-Term Debt | - | - | - | 2.82 | 4.5 |
Other Long-Term Liabilities | - | - | 0.31 | 0.35 | 0.15 |
Total Liabilities | 2.52 | 2.56 | 5.6 | 6.09 | 5.84 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 15.84 | 10.68 | 5.48 | 5.37 | 4.51 |
Retained Earnings | -20.97 | -15.29 | -12.49 | -12.38 | -8.74 |
Comprehensive Income & Other | 1.76 | 2.22 | 1.65 | 1.65 | - |
Total Common Equity | -1.27 | -2.38 | -5.35 | -5.36 | -4.23 |
Minority Interest | -0.06 | -0.06 | -0.05 | -0.06 | - |
Shareholders' Equity | -1.33 | -2.44 | -5.41 | -5.42 | -4.23 |
Total Liabilities & Equity | 1.19 | 0.12 | 0.19 | 0.67 | 1.61 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 2.24 | 2.24 | 4.98 | 4.97 | 4.5 |
Net Cash (Debt) | -2.17 | -2.18 | -4.84 | -4.64 | -3.15 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -0.35 | -4.24 | -14.54 | -16.85 | -23.57 |
Filing Date Shares Outstanding | 7.28 | 2.01 | 0.34 | 0.33 | 0.13 |
Total Common Shares Outstanding | 7.28 | 1.42 | 0.34 | 0.33 | 0.13 |
Working Capital | -1.33 | -2.44 | -5.1 | -2.25 | 0.42 |
Book Value Per Share | -0.17 | -1.68 | -15.85 | -16.11 | -31.64 |
Tangible Book Value | -1.27 | -2.38 | -5.35 | -5.36 | -4.23 |
Tangible Book Value Per Share | -0.17 | -1.68 | -15.85 | -16.11 | -31.64 |